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Michelle E Tougas1 and Lori Wozney1Abstract
Background: Prognosis research aims to identify factors associated with the course of health conditions. It is often
challenging to judge the overall quality of research evidence in systematic reviews about prognosis due to the
nature of the primary studies. Standards aimed at improving the quality of primary studies on the prognosis of
health conditions have been created, but these standards are often not adequately followed causing confusion
about how to judge the evidence.
Methods: This article presents a proposed adaptation of Grading of Recommendations Assessment, Development
and Evaluation (GRADE), which was developed to rate the quality of evidence in intervention research, to judge the
quality of prognostic evidence.
Results: We propose modifications to the GRADE framework for use in prognosis research along with illustrative
examples from an ongoing systematic review in the pediatric pain literature. We propose six factors that can
decrease the quality of evidence (phase of investigation, study limitations, inconsistency, indirectness, imprecision,
publication bias) and two factors that can increase it (moderate or large effect size, exposure-response gradient).
Conclusions: We describe criteria for evaluating the potential impact of each of these factors on the quality of
evidence when conducting a review including a narrative synthesis or a meta-analysis. These recommendations
require further investigation and testing.
Keywords: GRADE, Prognosis, Quality of evidenceBackground
Prognosis research examines the progression of a health
condition over time in order to identify risk and protect-
ive factors that can alter the likelihood of a future event
during the course of such a condition [1]. The evidence
about the progression of a health condition derived from
prognosis research is crucial to make informed decisions
about the process to identify individuals who are at risk
for poor outcomes, to facilitate early intervention and
guide the development of preventive interventions that
target modifiable prognostic factors [2]. Synthesizing re-
sults from prognosis research for these potential uses is,* Correspondence: anna.huguet@dal.ca
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reproduction in any medium, provided the orhowever, often challenging as primary study results are
often inconsistent and difficult to interpret [3]. Individ-
ual study differences may be due to, for example, small
sample sizes, adjustments for different variables in the
analyses, or consideration of different subsets within the
same population [4-7]. Standards have been proposed to
guide the design, procedures, analysis and reporting of
this research in an attempt to minimize the variability
and improve the quality of the primary studies [4-7].
However, these standards are often not followed causing
confusion about the prognostic value of individual fac-
tors [8] and limiting research application [9]. Due to the
important implications of this research for improving
health outcomes, providing guidelines about how to
judge the evidence of this widely varied research is ne-
cessary. This manuscript presents a system that can helpl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factor research [10]. We suggest that Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) [11] can be adapted for the assessment of evi-
dence derived from prognostic factor research.
GRADE: a framework to guide the judgment about the
quality of evidence in a systematic review
GRADE was first developed to provide methodological
guidance in reviewing intervention research; specifically,
how to rate the quality associated with estimated effects of
an intervention on a specific outcome, and how to grade
the strength of recommendations regarding the interven-
tion as part of a guideline development process [12]. When
making judgments about the quality of evidence, the
GRADE approach considers five factors that can decrease
our confidence in estimates of effects: (1) study design and
limitations in study design, (2) inconsistency of results
across studies, (3) indirectness of the evidence, (4) impreci-
sion and (5) publication bias; and three factors that can
increase our confidence in estimates of effects from obser-
vational studies: (1) large estimates of treatment, (2) a
dose–response gradient and (3) plausible confounding that
would increase confidence in an estimate. The GRADE
framework, widely used by researchers working on reviews
and guidelines, and groups providing recommendations for
health care professionals such as NICE [13], has also been
formally adapted for use in grading the quality of evidence
and strength of recommendation for diagnostic research
[14]. Recently, Goldsmith and colleagues have also pro-
posed using GRADE as a framework for prognostic studies
[15]. They used the framework and definitions of GRADE
to rate the quality of evidence for prognostic studies evalu-
ating cold hyperalgesia as a prognostic factor in whiplash-
associated disorders. They described the general frame-
work that was followed; however, they failed to address all
of GRADE's factors or provide enough information to
allow replication of their GRADEing process for prognostic
studies. The following sections outline specific aspects of
the modified GRADE framework (for example, how risk of
bias in primary prognosis studies were assessed), the
process used to modify the GRADE framework, and sug-
gestions for how to apply the new adapted framework to
systematic reviews where meta-analyses are lacking.Table 1 Definitions of the four quality categories according t
Development and Evaluation (GRADE) [16], applicable to the
High quality We are very confident that the true effect lies close to that
Moderate
quality
We are moderately confident in the effect estimate: the true
possibility that it is substantially different
Low quality Our confidence in the effect estimate is limited: the true eff
Very low
quality
We have very little confidence in the effect estimate: the tru
Reprinted from [16] with permission from Elsevier.Applying the GRADE framework to prognosis research
Consistent with the GRADE principles, when synthesizing
the evidence from prognosis research it is important to esti-
mate the effect of a factor on an outcome and also to report
the level of confidence in these findings. Therefore, in a sys-
tematic review of prognostic factors it is recommended to
assess the quality of evidence for each outcome of interest
across studies. Our team has applied the GRADE frame-
work and concepts to assess the quality of a body of evi-
dence from prognosis studies into four quality categories
(high, moderate, low, and very low) according to the trad-
itional GRADE framework (Table 1). Along with our de-
scriptions of how the GRADE framework can be adapted
and used in this kind of research, we provide examples
from a recent systematic review of prognostic studies
conducted in the field of recurrent pain in children and
adolescents (Table 2) (Huguet A, et al., in preparation)
Since there are times when it is not appropriate or pos-
sible to conduct meta-analysis of prognostic evidence due
to diversity within the studies included in the review or to
poor methodological quality, or both, we also describe var-
iations on how to implement the GRADE systematic re-
view framework when conducting a narrative synthesis.
We are not presenting a formalized guideline. Our recom-
mendations are based on the discussions between the co-
authors and our experience conducting systematic reviews
of prognostic research on pain.
GRADE framework for prognosis
We think most of the factors taken into consideration by
the GRADE framework to rate the quality of evidence from
intervention research are conceptually applicable when ap-
plying the GRADE to judge the quality of evidence from
prognostic research. However, our proposed assessment
approach to determine how much each of these factors in-
fluence the quality of evidence is different from the ap-
proach originally suggested for intervention research.
Table 3 compares the factors that may lead to rating down
or up the quality of evidence from intervention research
with the factors that may lead to rating down or up the
quality of evidence from prognosis research. Notable differ-
ences when rating the quality of evidence from prognostic
research include the following. (1) When judging the qual-
ity of prognostic evidence the study design is noto the original Grading of Recommendations Assessment,
modified GRADE
of the estimate of the effect
effect is likely to be close to the estimate of the effect, but there is a
ect may be substantially different from the estimate of the effect
e effect is likely to be substantially different from the estimate of effect
Table 3 Factors that may increase and decrease the
quality level of evidence
Evidence about intervention [16] Evidence about prognosis
Factors that may decrease the quality
1. Research design 1. Phase of investigation
2. Study limitations 2. Study limitations
3. Inconsistency 3. Inconsistency
4. Indirectness 4. Indirectness





Huguet A, et al.,
in preparation
We have conducted a systematic review of the literature examining risk and protective factors for the onset and course of
several chronic pain conditions in children and adolescents. The scope of this review is very broad because we have
considered multiple etiological and prognostic factors combined with multiple outcomes.
Through a search of PubMed, EMBASE, PsycInfo, CINAHL, and Web of Science from inception until February 2013, we included all
manuscripts that meet the following criteria: studies were included if they were a cohort prospective or retrospective study with
at least 3 months of follow-up quantitatively investigating through inferential statistics the prediction of the onset, persistence of
chronic or recurrent pain conditions and pain-related disability from childhood or adolescence. Studies were excluded if they
were non-English or the population had cognitive impairments or life threatening illnesses.
Throughout this article we will provide examples of evidence of potential risk and protective factors associated
with the course of headaches in children and adolescents in an attempt to provide a practical overview of the
application of the GRADE for prognostic evidence.
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acceptable ones that provide prognostic evidence (design
characteristics are considered in the risk of bias assess-
ment). (2) Using the GRADE framework to evaluate the
quality of evidence from prognosis research should begin
with the phase of investigation. (3) Plausible confounding
does not need to be considered as an additional factor to
rate up the quality of evidence. Two main reasons lead us
to this decision. First, the potential effects of confounding
in both intervention and prognosis research are not
interpreted in the same direction. In intervention research,
the assumption is that lack of control for confounding can
inflate the reported effect sizes, so that the intervention
appears to be more effective than it actually is when evi-
dence is from studies that do not adequately control for
confounding. This assumption is not made in prognostic
research. It is often unclear how confounders alter effect
sizes in prognostic studies. Second, plausible confounding
is indirectly considered when assessing risk of bias. When
assessing risk of bias, we are not evaluating how this will
influence the strength of the effect; rather, we are evaluating
the internal validity of the studies. As we describe below in
more detail, when considering the potential impact of study
limitations on the quality of evidence from prognostic re-
search, the reviewers should consider downgrading the
quality of evidence for methodological limitations when
analyses are not adequately adjusted for confounders
(which may be responsible for spurious or attenuated rela-
tions between the factor and the outcome).
Next we describe the assessment approach for consid-
ering the potential effect of each of these factors on the
quality of evidence.5. Imprecision 5. Imprecision
6. Publication bias 6. Publication bias
Factors that may increase the quality
1. Large effect size 1. Moderate or large effect size
2. Exposure-response gradient 2. Exposure-response gradient
3. Plausible confoundingPhase of investigation
When evaluating the overall quality of evidence, we sug-
gest that researchers consider the phase of investigation. A
high level of evidence for prognosis is derived from a co-
hort study design that seeks to generate understanding ofthe underlying processes for the prognosis of a health con-
dition, called a phase 3 explanatory study, or a cohort
study design that seeks to confirm independent associa-
tions between the prognostic factor and the outcome,
called phase 2 explanatory studies [4,7]. Prospective or
retrospective cohort studies that test a fully developed hy-
pothesis and conceptual framework without serious study
limitations, and confirmatory studies without serious limi-
tations constitute high-quality evidence on prognosis.
These studies should be prioritized as primary studies. In
emerging areas of research, there may be a lack of avail-
able primary studies that meet this criterion. In this in-
stance, predictive modeling studies or explanatory studies
conducted in the earlier phase of investigation to generate
a hypothesis (phase 1 explanatory studies) may be in-
cluded. These studies should be judged as providing
weaker evidence. Therefore, we propose that the starting
point for the quality level of the evidence should be based
on phase of investigation (see Table 4). Table 5 illustrates
an example of the effect of phase of investigation as a
starting point for judging the quality of evidence.
Table 4 Guide to judge the quality of evidence for prognosis
Phase of investigation Quality of
evidence
Downgrade if: Upgrade if:
Explanatory research aimed to understand prognostic pathways
(phase 3 explanatory study) and explanatory research aimed to
confirm independent associations between potential prognostic
factor and the outcome (phase 2 explanatory study)
High Study limitations: Moderate or large effect:
- Serious limitations when most evidence is from studies with
moderate or unclear risk of bias for most bias domains
- For meta-analysis: pooled
effect is moderate or large,
- Very serious limitations when most evidence is from studies
with high risk of bias for almost all bias domains
- For narrative summary: moderate
or large similar effect is reported
by most studies
Inconsistency: Exposure-gradient response
Unexplained heterogeneity or variability in results across studies with
differences of results not clinically meaningful. This may be supported by:
- For meta-analysis: gradient is
present between analyses for
factors measured at different doses
- For meta-analysis: significant heterogeneity detected by test
of heterogeneity and large I2 value.
- For narrative summary: possible
gradient exists within and between
primary studies
- For narrative summary: variations in effect estimates across studies
with points of effect on either side of the line of no effect, and
confidence intervals showing minimal overlap
Indirectness:
Outcome prediction research or explanatory research aimed to
identify associations between potential prognostic factors
and the outcome (phase 1 explanatory study)
Moderate The study sample, the prognostic factor, and/or the outcome
in the primary studies do not accurately reflect the review question
Imprecision:
- For meta-analysis: (1) insufficient sample size and (2) no precise estimate of
the effect size in the meta-analysis: confidence interval is excessively wide and
overlaps the value of no effect and contain values implying that the factor plays
an important role in protecting or putting the individual at risk
Low - For narrative summary: within-study imprecision: (1) sample size justification is not
provided and there are less than 10 outcome events for each prognostic
variable (for dichotomous outcomes) OR there are less than 100 cases reaching
endpoint (for continuous outcomes), and (2) no precision in the estimation of
the effect size within each primary study, AND
Very low
- Across study imprecision: there are few studies and small
number of participants across studies.
Publication bias:
We recommend downgrading unless:
- The value of the risk/protective factor in predicting the outcome
























During the selection process of our review for risk or protective factors of the course of “headache”, a common recurrent pain condition,
we did not put any restriction on phase of investigation. We did this because, in the child pain prognosis literature, studies are rarely
grounded in theoretical frameworks so there are rarely any phase 3 explanatory study published [17] and phase 2 exploratory studies are
not very common. Therefore, our review majorly includes phase 1 exploratory studies that identify potential prognostic factors which are
particularly vulnerable to type I errors (false positive results). Consequently, the quality of evidence from the studies selected in
our review could not be initially rated high.
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evidence can be upgraded or downgraded according to
the following additional criteria.
Reasons for downgrading the quality of evidence
Study limitations
The findings derived from individual prognostic studies
are often limited for their methodological shortcomings.
There are several tools available for assessing methodo-
logical limitations [18-20]. We recommend using the
Quality in Prognosis Studies (QUIPS) tool [19,20], which
rates individual studies according to the potential risk of
bias associated with six domains: (1) study participation,
(2) study attrition, (3) prognostic factor measurement,
(4) outcome measurement, (5) confounding measure-
ment and account, and (6) analysis. This tool, designed
for use in prognostic factor studies to comprehensively
assess risk of bias based on epidemiological principles,
has demonstrated acceptable reliability [20]. The level of
risk of bias associated with each domain can be rated as
‘low’, ‘moderate’ and ‘high’ based on the responses that
reviewers give to each item.
We suggest that, when assessing the risk of bias of a
prognostic factor across studies for a specific outcome, re-
viewers should rate the evidence as having: (1) no serious
limitations when most evidence is from studies at low risk
of bias for most of the bias domains; (2) serious limitations
when most evidence is from studies at moderate or unclear
risk of bias for most of the bias domains; or (3) very serious
limitations when most information is from studies at high
risk of bias with respect to almost all of the domains.
Table 6 illustrates an example. As is similar to what hap-
pens when GRADE is used for intervention research, the
study limitations are outcome and factor specific [21].
Consequently, one study may be associated with higher
risk of bias when referring to one outcome or to one prog-




When conducting our comprehensive systematic review of pro
evidence of headache severity as a prognostic factor for persiste
studies [22-24] and all of them have moderate risk of bias. The s
for important potential confounders in the design and in the an
(in [23,24]), selective reporting of results (in [23,24]), and not usin
we sometimes observed no description of inclusion/exclusion c
and inadequate information about participation rate (in [22-24])factor of interest. We advise conducting subgroup analyses
to explore the impact of studies with high risk of bias on
specific domains and from the overall review (that is, ser-
ious or very serious limitations). Sensitivity analyses may
be conducted to restrict the synthesis to studies with lower
risk of bias. These steps will inform how the study limita-
tions influence the size of the effect. If studies with ‘serious
limitations’ or ‘very serious limitations’ are included in the
body of evidence to be evaluated, specific justification in a
footnote for the relevant tables is suggested.Inconsistency
Inconsistency occurs when there is unexplained hetero-
geneity or variability in results across studies. When this
happens, the quality of evidence decreases. Different ap-
proaches to assess inconsistency can be applied if the
systematic review incorporates narrative synthesis or
meta-analysis.
To evaluate whether inconsistency exists, we recom-
mend that reviewers employing meta-analysis base their
decisions on their judgment of whether a clinically mean-
ingful difference exists between the point estimates and
their confidence intervals of primary studies in the review
context, as well as statistical parameters derived from their
meta-analyses. Reviewers may consider downgrading the
quality of evidence for inconsistency when they observe
the following statistical parameters as long as these differ-
ences are clinically meaningful: (1) estimates of the effect
of the prognostic factor on the outcome vary across stud-
ies with the points of effect on either side of the line of no
effect and their confidence intervals show minimal or no
overlap; (2) the statistical test for heterogeneity, which
tests the null hypothesis that all studies in a meta-analysis
have the same underlying magnitude effect, shows a low P
value; and (3) the I2, which quantifies the proportion of
the variation in point estimates due to true studying quality of evidence
gnostic factors of headaches in children, we reported for example that the
nce of headache had serious limitations. This evidence comes from three
ources of potential bias in these studies were: not appropriately accounting
alysis (in [22-24]), not presenting sufficient data to assess adequacy of analysis
g any conceptual framework when building a model (in [22-24]). Moreover,
riteria (in [23]), no description of sample frame and recruitment (in [23,24]),
.
Table 7 The effect of considering inconsistency when judging quality of evidence
Factor Example
Inconsistency Our narrative systematic review included three studies examining chronological age as a prognostic factor for persistence of headache [26-28].
While Larsson and Sund [27] found in a 1-year cohort study with 2,465 schoolchildren aged between 12 and 15 years that the risk of
persistence of frequent headaches increases with age (odds ratio = 1.88, 95% confidence interval = 1.65 to 2.15), Kienbacher and colleagues
[26] and Wang and colleagues [28] did not reach the same conclusion when running longer term follow-up studies with children and
adolescents with a headache diagnosis. Kienbacher and colleagues [26] performed a follow-up study on 227 children and adolescents with
migraine or tension-type headache. The average follow-up period was 6.6 years, with the age ranging from 5 to 8 years. Wang and colleagues
[28] performed an 8-year follow-up study with adolescents with migraine. In both cases, age was reported not to be associated with
persistence of headache. There is inconsistency of results across these three studies; however, neither of the two longer term cohort studies
reported either means and a measure of variance or results from the statistical analyses to judge the level of overlap of the confidence
intervals between the three studies. Duration of the follow-up, outcome and headache population were very different across studies. As far as
the duration of the follow-up is concerned, despite the fact that the cohort study with short-term follow-up reported a significant risk estimate
for an advanced age which was not found in cohort studies with longer term follow-ups, we did not find a plausible explanation for such
potential influence of the duration of follow-up on the association between age and persistence of headaches. However, the outcome and
the headache population could explain some of this heterogeneity [29]. Consequently, we did not consider the inconsistency across findings
examining chronological age as a prognostic factor for headache persistence to be very serious and rated this item as serious inconsistency.
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stantial (that is, 50% or greater [25]).
Potential inconsistency related to differences in the mag-
nitude of effects, as described above, should ideally be ex-
plored with a priori defined subgroup analyses. Differences
in the population, the duration of follow-up, the outcome,
the prognostic factor, or study methods across studies may
explain differences. In this case, we propose to estimate
separate effects accordingly. If, after running separate sub-
group meta-analyses, this hypothesis is supported by the
data, we suggest that reviewers consider presenting separ-
ate pooled estimates instead of estimating an overall com-
bined effect.
If a meta-analysis is not conducted, we recommend that
reviewers consider downgrading for inconsistency when
estimates of the prognostic factor association with the out-
come vary in direction (for example, some effects appear
protective whereas others show risk) and the confidence
intervals show no, or minimal overlap. See an example in
Table 7.
Inconsistency cannot be assessed when only a single
study within the existing body of literature has estimated
the effect. In these cases, this criterion may be consideredTable 8 The effect of considering indirectness when judging
Factor Example
Indirectness in population In our review we were interested in all headache s
examined the type of headache (that is, migraine o
All three studies recruited participants from headac
sufferers in the general population. It is likely that o
to a headache specialist [32]. We therefore downg
headache persistence for serious indirectness.
Indirectness in prognostic
factor
We cannot provide examples extracted from our re
factor. Instead our goal has been to explore all type
protective factors for the persistence of a variety of
representation would happen, for example, if we we
persistence of recurrent headaches and the primary
of depression diagnosis on onset of headaches.
Indirectness in outcome For example, this poor representation of outcome
factor for the persistence of recurrent headaches a
persistence of migraine (and at least not all types oas ‘not applicable’. However, we still recommend the re-
viewers to downgrade the quality of evidence since this is
an indicator that the literature is not well established in
the area. If observed inconsistency is unexplained, re-
viewers should decide whether the inconsistency is serious
or very serious and justify why they have made this deci-
sion with a footnote.
Indirectness
Indirectness exists when the participant population, prog-
nostic factor(s) and/or outcomes considered by re-
searchers in the primary studies do not fully represent the
review question defined in the systematic review. The
judged quality of evidence decreases because the results
derived from the primary studies are less generalizable for
the purpose of the systematic review.
Regardless of whether reviewers perform a meta-analysis
or not, downgrading the quality of evidence for indirect-
ness is appropriate when: (1) the final sample only repre-
sents a subset of the population of interest (an example of
indirectness in population is displayed in Table 8); (2) when
the complete breadth of the prognostic factor that is being
considered in the review question is not well representedquality of evidence
ufferers. There were three longitudinal studies in the literature that
r tension-type) as a prognostic factor for headache persistence [24,30,31].
he clinics. These populations are not representative of all headache
nly those with more severe and frequent headache conditions are referred
raded the body of evidence on type of headache as a prognostic factor of
view since our review was not intentionally limited to a specific prognostic
s of factors that have been investigated to date as potential risk or
chronic pain conditions and their associated disability. However, this poor
re interested in exploring the effect of mental illnesses on the
studies included were only investigating the prognostic value
would happen if we were interested in exploring whether race is a risk
nd the outcome was represented by studies assessing only the
f the main primary headache disorders).
Table 9 The effect of considering imprecision when judging quality of evidence
Factor Example
Imprecision Menstruation in girls is another potential prognostic factor investigated in the pediatric headache literature. Wang and colleagues [22], the only
study in our review that investigated this factor, sought to explore the prognostic value of menses in girls on migraine persistence in two
follow-up annual surveys with a sample of 449 junior high school students with migraine. In their study, 134 out of 449 participants reported
persistent migraine for all 3 years. Multiple logistic regression was used to explore the association between 14 potential prognostic factors
(including menses in girls) and migraine persistence. This analysis has sufficient statistical power. No significant association between menses and
persistent migraine was found; however, no effect size or confidence interval values were provided, so conclusions regarding the level of
imprecision of the estimated effect of the menses remain unclear. Consequently, we considered the level of imprecision as unclear.
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or (3) when the outcome that is being considered in the re-
view question is not broadly represented (an example is
displayed in Table 8).
Downgrading the quality of the evidence with respect
to indirectness depends on how extreme the differences
are and how much these differences can influence the
magnitude of effect. Reviewers should make this judg-
ment based on the purpose of their review.Imprecision
Random error or imprecision exists when the evidence
is uncertain, leading to different interpretations about
the relationship between the prognostic factor and its as-
sociated risk or protective value.
To judge whether the results of meta-analysis have
sufficient precision a reviewer should first consider
whether the number of participants included in the
meta-analysis is appropriate through sample size estima-
tion (similar to sample size estimates for a single study,
but accounting for between-study heterogeneity; see Bull
[33] for a discussion of the need of an adequate sample
size in a meta-analysis). Second, if the number of partici-
pants included in the meta-analysis is appropriate, based
on their best judgment, reviewers should consider the
results precise when the confidence interval around the
estimated effect size is not excessively wide while includ-
ing values implying that the prognostic factor is associ-
ated with protection or increased risk.
Evaluating the imprecision when a meta-analysis is not
possible is challenging. The best approach is for re-
viewers to judge the overall precision based on precision
of results within each study while taking into accountTable 10 The effect of considering publication bias when jud
Factor Example
Publication bias In our review, we identified research evaluating whether fem
over time. Four longitudinal studies [28,37-39] at an early pha
these studies explored the effect of female sex while includin
and colleagues [38] reported female sex to be a significant ri
other co-variables (for example, anxiety, self-esteem, stressful
Wang and colleagues [28] reported no effect when adjusted
psychiatric comorbidities. We considered this association exp
for early phase of investigation we decided not to downgradthe number of studies and participants involved. If the
majority of studies included in the review are precise, re-
gardless of the number of studies and sample size, re-
viewers should not downgrade the quality of evidence
for imprecision. To estimate whether the primary studies
included in the review are unpowered or not, reviewers
should take into account the sample size that each of
the primary studies used. To do this, they should explore
whether the authors of the primary studies provided any
rationale for the sample size. Authors of prognostic
studies should estimate an effect size and select the de-
sired power beforehand, and then calculate the sample
size needed in order to achieve that power and to detect
the specified effect size [5,33]. If authors do not provide
such rationale, reviewers can consider the sample size
appropriate for studies using dichotomous outcomes
using the ‘rule of thumb’, when there are at least 10 out-
come events for each potential prognostic variable con-
sidered in the analysis [4,34]. If insufficient information
is available to determine appropriateness of sample size,
or studies use continuous outcomes, the sample size can
be considered appropriate when there are at least 100
cases that reached the endpoint [35]. If the sample sizes
are large enough, the reviewers should then evaluate the
width of the interval. If most of the confidence intervals
reported in each study include both no effect and appre-
ciable risk and protective values, the evidence derived
from that particular study is imprecise. At that stage, to
evaluate the overall imprecision for the explored prog-
nostic factor association, we recommend reviewers to
also consider the number of studies, and number of par-
ticipants across studies, because there is likely to be
more imprecision with a fewer number of studies and/or
participants. Consequently, we recommend downgradingging quality of evidence
ale (rather than male) sex can increase the risk for persistence of headache
se of investigation, explored this potential factor in multivariate analyses. All
g important potential confounders in the multivariate model. While Stanford
sk factor when sex was entered simultaneously into the model with
life events), Monastero and colleagues [37], Termine and colleagues [39] and
for potential confounders such as age, medication overuse, age of onset, and
lored by an adequate number of studies, and since we already downgraded
e the quality of this evidence for publication bias.




For our review, we upgraded evidence for large or moderate effect sizes. For example, our review included two studies that
examined through univariate analyses whether family history of headaches predicts migraine persistence. Monestero and colleagues
[37] reported a significantly large effect (odds ratio = 6.2), while Ozge and colleagues [43] also examined the same relationship and
reported a small-moderate effect size (odds ratio = 2.08). Collectively we felt these effect sizes were large enough to warrant
upgrading the evidence, indicating that the relationship between family history of headache and persistence probably exists.
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few studies involving a small number of participants and
most of the studies provide imprecise results. See an ex-
ample in Table 9.Publication bias
This is a very important factor in prognostic study evi-
dence because investigators often fail to report rela-
tionships that show no effect between potential
prognostic factors and outcomes. This happens when
published evidence is restricted to only a portion of the
studies conducted on the topic [36]. The current lack
of an existing register for prognostic research studies
prevents reviewers from making an informed judgment
about whether there is evidence that publication bias is
a potential problem. Consequently, a prudent default
position at this moment is to assume that prognosis re-
search is seriously affected by publication bias until
there is evidence to the contrary [6]. Reviewers should
consider that publication bias exists across all factors
except in those cases in which they find that a deter-
minate prognostic factor has been investigated in a
large number of cohort studies. Ideally, most of these
large numbers of studies should have been designed to
purposefully confirm the hypothesized independent ef-
fect of the factor on the outcome (phase 2 study) or to
test a conceptual model which explains its underlying
mechanisms (phase 3 study). However, since phase of
investigation is already taken into account as a factor
that can downgrade the overall quality of evidence, we
do not recommend downgrading again for publication
bias due to only phase of investigation. For these cases,
reviewers conducting a systematic review with or with-
out meta-analysis may judge that there is less likely to
be publication bias (see Table 10).Table 12 The effect of considering exposure gradient when ju
Factor Example
Exposure gradient In our review we did not observe evidence of an
an exposure-response gradient is observed in a c
because cross-sectional studies should not be us
a sample of adults with frequent headaches, whe
and household dysfunction) prior to and includin
in adulthood. A significant exposure-response gr
associated with the likelihood of headache in ad
childhood adverse events also increases from 1, tReasons for rating up the quality of evidence
Moderate or large effect size
Multiple prognostic factors often contribute to the prog-
nosis of health conditions. Therefore, finding a moderate
or large effect size is one of the key criteria for rating up
the quality of evidence. A moderate or large effect size
increases the likelihood that a relationship between the
prognostic factor and the outcome does in fact exist.
Reviewers should rate up the quality of evidence when
they find a moderate or large pooled effect of the meta-
analysis. ‘Rules of thumb’ have been proposed to judge the
effect moderate or large (for example, standardized mean
difference statistic = around 0.5 for moderate effect or
around 0.8 or larger for large effect [40], odds ratio =
around 2.5 for moderate effect or 4.25 or greater for large
effect [41,42]). However, because these are arbitrary guide-
lines, a sensible decision should be made and justified by
the reviewers taking into account the study context (for
example, background risk and unit of measurement).
If it is not possible to conduct a meta-analysis, re-
viewers should rate up the quality of evidence when they
find moderate or large similar effects reported by most
of the primary studies (see an example in Table 11).
Exposure-response gradient
An exposure-response gradient exists when elevated levels
of the prognostic factor (for example, larger amount, lon-
ger duration, higher intensity) lead to a larger effect size
over lower levels of the factor. The presence of such a gra-
dient increases confidence in the findings that the factor is
associated with an increased risk or protective value and
therefore raises our rating of the quality of evidence.
When conducting systematic reviews with meta-analysis,
the reviewers should observe whether an exposure-
response gradient is present between subgroup analyses for
factors measured at different doses.dging quality of evidence
exposure-response gradient in any of the cases identified. However,
ross-sectional study of headache, which was not included in our review
ed to study causes and prognosis. Anda and colleagues [44] evaluated, in
ther the number of adverse childhood events (including childhood abuse
g the age of 18 was associated with the presence of self-reported headaches
adient was identified, with an increase in the size of the odds ratio
ulthood from 1.2, to 1.7, to 2.1 as the number of
o 3, to 5, respectively.
Table 13 Example of an adapted Grading of Recommendations Assessment, Development and Evaluation (GRADE) table for systematic reviews with










































Table 14 Example of an adapted Grading of Recommendations Assessment, Development and Evaluation (GRADE) table for narrative systematic reviews of
prognostic studies (filled in with examples of our own review illustrated in the boxes throughout this manuscript)
Outcome: Headache persistence









+ 0 - + 0 - Phase Study
limitations








Headache intensity 536 3 [22-24] 3 1 2 0 1 ✕ ✓ ✓ ✓ ✕ ✕ ✕ +
Age 867 3 [26-28] 3 1 2 0 1 ✕ ✕ ✓ ✓ ✕ ✕ ✕ +
Type of headache
diagnosis
249 3 [24,30,31] 3 2 1 0 1 ✕ ✓ ✕ ✓ ✕ ✓ ✕ +
Menstruation 449 1 [22] 1 0 1 0 1 ✕ ✕ ✕ Unclear ✕ ✕ ✕ +
Sex 3,272 4 [28,38-40] 4 1 2 0 1 3 0 1 ✕ ✓ ✓ ✓ ✓ ✓ ✕ +++
Family history
of pain
654 2 [38,44] 2 2 0 0 1 1 0 1 ✓ ✕ ✕ ✓ ✕ ✓ ✕ +
Phase, phase of investigation. For uni- and multivariate analyses: +, number of significant effects with a positive value; 0, number of non-significant effects; -, number of significant effects with a negative value. For
GRADE factors: ✓, no serious limitations; ✕, serious limitations (or not present for moderate/large effect size, dose effect); unclear, unable to rate item based on available information. For overall quality of evidence:
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http://www.systematicreviewsjournal.com/content/2/1/71If a meta-analysis or subgroup analyses are not
conducted, or only one meta-analysis is conducted for
the relationship between a prognostic factor and outcome,
reviewers should observe whether a possible exposure-
response gradient consistently exists within and between
primary studies. The use of the same measures to evaluate
prognostic factors and outcomes across studies is a
required condition to appropriately evaluate the possible
existence of this gradient between studies. Table 12
displays an example.
The findings derived from the GRADE framework to
judge the evidence derived from prognostic studies can be
presented in the proposed summary of findings tables (see
Tables 13 and 14).Conclusions
This article is a first attempt to outline how GRADE
may be adapted to assess the quality of evidence for
prognostic research studies for a systematic review of
the literature. To date, a formal system to guide resear-
chers in assessing the evidence for prognostic studies
has been lacking. Our adaptation is a first step in devel-
oping a systematic approach to evaluate the quality of
evidence for prognostic research. We encourage these
recommendations to be further developed and tested for
GRADEing the quality of evidence when synthesizing
findings from prognostic research studies. For instance,
further guidance for reviewers is needed to decide when
each of these GRADE factors causes the evidence to be
down- or upgraded one versus two levels. At this stage,
we leave this decision up to the judgment of the review
teams to decide how much these factors impact the
overall quality of evidence. Empirical research is also
needed to explore our hypothesis that risk of bias detri-
mentally affects the factor-outcome relationship and
what the strength of this relationship is.Abbreviations
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